Video: Legislation, FTC Interim Report Positive Progress in Fight for PBM Reform
Drug Topics
AUGUST 20, 2024
Bipartisan support—in a polarized Congress—underscores the importance of pharmacy benefit manager reform.
Tue.Aug 20, 2024
281 
23andMe inches closes to cancer immunotherapy, guided by its genetic database
PharmaVoice
AUGUST 20, 2024
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pharmacists Play Key Role in Warning Patients About Harms of Sourcing GLP-1s Online
Drug Topics
AUGUST 20, 2024
Timothy Mackey, MAS, PhD, discusses the dangers associated with sourcing GLP-1s from illegal online pharmacies and the key role pharmacists play in warning patients.
Integration of Palliative Pharmacists to Elevate Oncologic Care
Pharmacy Times
AUGUST 20, 2024
Palliative pharmacists are invaluable assets of oncologic care.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Grants Tentative Approval to Treprostinil for PAH Associated With PH-ILD
Drug Topics
AUGUST 20, 2024
Final approval of the therapy may occur after expiration of the 3-year regulatory exclusivity for Tyvaso DPI on May 23, 2025.
Opinion: Mask bans disenfranchise millions of Americans with disabilities
STAT
AUGUST 20, 2024
Last week, a mask ban in Nassau County, New York was signed into law. If I lived just 60 miles east of my New Jersey town, I would be under threat of a fine or jail time every time I left the house. I’ve been masking consistently in public since 2020, when the Covid-19 pandemic began, because I have a kidney transplant and will take immunosuppressant medication for the rest of my life.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
STAT+: Lilly’s Zepbound slashed risk of developing diabetes
STAT
AUGUST 20, 2024
Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In a Phase 3 trial that lasted over three years, people with pre-diabetes taking Zepbound had a 93% lower risk of progressing to diabetes compared with people on placebo, Lilly said Tuesday.
Amidst Push for PBM Reform, NACDS Grassroots Efforts Bloom
Drug Topics
AUGUST 20, 2024
Inviting members of Congress into the pharmacy helps legislators experience first hand the value that pharmacists bring to their communities.
Epic touts new AI applications to streamline charting and bring research insights to the point of care
Fierce Healthcare
AUGUST 20, 2024
Health IT giant Epic is pushing ahead rapidly to build out artificial intelligence technologies and generative AI features in its electronic health record software. | The goal, according to Epic executives, is to ease the documentation burden for clinicians, streamline charting and coding and bring evidence-based medical insights and research right to doctors' fingertips at the point of care.
Does Ozempic increase the risk of suicidal thoughts? A new study muddles the picture
STAT
AUGUST 20, 2024
A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs, though experts raised concerns about the methodology and the findings contradict what some other studies have found about the class of GLP-1 diabetes and obesity drugs. Academic researchers analyzed a World Health Organization database that tracks suspected adverse drug reactions, and found that there was a 45% greater rate of reports of suic
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Expert: Emphasis on Diabetes Research Can Close Gaps in Marginalized Communities
Pharmacy Times
AUGUST 20, 2024
Jasmine Perry discusses the More Than a Script program in an interview with Pharmacy Times.
STAT+: Q&A: How the FDA could use AI for drug and device safety surveillance
STAT
AUGUST 20, 2024
The Food and Drug Administration’s responsibilities don’t end when a drug hits the market after it’s approved: the agency is also continuously assessing products after they’re widely available for any safety issues. And a group of researchers — including two from the FDA’s Center for Drug Evaluation and Research — think artificial intelligence could uncover more signs of these issues, including from electronic health records, social media posts, a
GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer
Pharmacy Times
AUGUST 20, 2024
The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.
STAT+: Congressional probe questions clinical trials run in China, citing Army involvement
STAT
AUGUST 20, 2024
A House committee is investigating whether brand drug companies are collaborating with the Chinese military when they run clinical trials in that country. “For over a decade, it appears that U.S. biopharmaceutical companies conducted clinical trials with China’s military organizations, and specifically with medical centers and hospitals affiliated with the People’s Liberation Army’s,” according to an Aug. 19 letter that the House China committee sent to t
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors
Pharmacy Times
AUGUST 20, 2024
Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.
STAT+: What to know about Alnylam’s upcoming readout on its heart drug
STAT
AUGUST 20, 2024
Next week, the biopharma world will see eagerly awaited results from a trial that could shape care for patients with an increasingly common heart condition — and determine which companies stand to reap billions. The trial of vutrisiran, from Alnylam Pharmaceuticals, was already announced as positive , with the drug successfully cutting the risk of death and cardiovascular complications in patients with the disease, called transthyretin amyloid cardiomyopathy, or ATTR-CM.
Medicare Advantage's growth a bad omen for hospitals, S&P Global warns
Fierce Healthcare
AUGUST 20, 2024
The upward trajectory of Medicare Advantage (MA) enrollment is likely to become an issue for hospitals and other healthcare providers forced to contend with plans’ prior authorization requirements | Prior authorization burdens and "a challenging contract negotiation season" on the horizon are likely headwinds for providers, and hospitals in particular, according to a recent report.
Teamwork is good for science — but maybe not for young researchers’ careers
STAT
AUGUST 20, 2024
Science is a team sport, and those teams are getting larger. While that expansion might help researchers answer complex biomedical questions by working together, a recent study suggests that this trend has hampered the career prospects of Ph.D. graduates. The authors analyzed 40 years of data from a National Science Foundation survey that tracks Ph.D. graduates.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
GSK bags breakthrough status for B7-H3 ADC for lung cancer
pharmaphorum
AUGUST 20, 2024
GSK gets FDA breakthrough status for its B7-H3 directed ADC, licensed from Hansah Pharma in a $1.
New study suggesting suicidal ideation risk for Novo's Ozempic adds to ongoing safety debate
Fierce Pharma
AUGUST 20, 2024
Regulators in both the U.S. and Europe have looked into the potential link between suicidal thoughts and Novo Nordisk’s blockbuster semaglutide franchise after reports sounded the alarm last year. | Researchers found that users of Novo's semaglutide who were logged in a WHO database were more likely to report suicidal ideation.
Employers are bracing for healthcare costs to spike in 2025. Here's why
Fierce Healthcare
AUGUST 20, 2024
Employers are up against escalating healthcare costs, driven by mounting prescription drug expenses, inflation and worsening chronic conditions, a new survey shows. | Employers are up against escalating healthcare costs, driven by mounting prescription drug expenses, inflation and worsening chronic conditions, a new survey shows.
Lawmakers urge FDA to investigate clinical trials run in tandem with China's military
Fierce Pharma
AUGUST 20, 2024
As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. | As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem.
Payer Roundup—Devoted Health raises $112M; L.A. Care eliminates prior auth codes
Fierce Healthcare
AUGUST 20, 2024
Below is a roundup of payer-centric news headlines you may have missed during the month of August 2024. | This month, Devoted Health completed its series E funding round, L.A. Care Health Plan slashed prior auth codes for catheter supplies, and Illinois signed laws cracking down on insurers involving colonoscopies, inhalers and more.
CDK9 inhibitors: Disrupting cancer cell growth and the treatment paradigm
pharmaphorum
AUGUST 20, 2024
Learn about the exciting potential of CDK9 inhibitors in disrupting cancer cell growth and changing the treatment landscape for cancer patients. Stay updated on the latest research and developments in this promising field.
J.D. Power: MA plans beat commercial coverage on consumer satisfaction
Fierce Healthcare
AUGUST 20, 2024
Amid significant scrutiny from lawmakers and regulators on Medicare Advantage, a new report suggests that consumer satisfaction with these plans is notably higher than with commercial insurance.
FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC
Pharmacy Times
AUGUST 20, 2024
The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).
STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more
STAT
AUGUST 20, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our window is picking up and the official mascots are busy foraging for their breakfast on the campus grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is maple bourbon. Yes, this is real.
Buoyed by muscular dystrophy data, Avidity raises $345m
pharmaphorum
AUGUST 20, 2024
Avidity Bio raises $345m from its second big public offering of 2024, after reporting encouraging Duchenne muscular dystrophy data.
Opinion: Improving the FDA-EMA parallel scientific advice program to advance complex generics
STAT
AUGUST 20, 2024
Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics and biosimilars — represent a system-critical industry that delivers around 80% of medicines used worldwide at a fraction of the cost of branded medicines.
Lilly adds to tirzepatide's impressive pedigree with new data showing the med helps stave off diabetes
Fierce Pharma
AUGUST 20, 2024
Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show. | Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show.
Expert says supplies of mpox vaccine unlikely to suffice
pharmaphorum
AUGUST 20, 2024
Emergent BioSolutions has agreed to donate 50,000 doses of its mpox vaccine for use in the current outbreak, but an expert has warned supplies are unlikely to meet demand
Carbon Health founder steps back from top role, Kaiser hospitals roll out AI scribe
STAT
AUGUST 20, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Carbon Health founder steps back from top role Carbon Health ‘ s chief executive and co-founder Eren Bali is taking a step back from the primary care tech company, returning instead to the education company Udemy he co-founded as its chief technology office
Changing Faces – Pharma and Biotech July 2024
pharmaphorum
AUGUST 20, 2024
Discover the latest news and updates on AbbVie, Sitryx, DiogenX, and more in the pharmaceutical and biotech industry in July 2024 with Changing Faces. Stay informed with the latest developments.
Let's personalize your content